These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18089967)

  • 21. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
    Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunosuppressive strategies to improve outcomes of kidney transplantation.
    Tang IY; Meier-Kriesche HU; Kaplan B
    Semin Nephrol; 2007 Jul; 27(4):377-92. PubMed ID: 17616271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential influence of tacrolimus and steroid avoidance on early graft function in pediatric renal transplantation.
    Li L; Weintraub L; Concepcion W; Martin JP; Miller K; Salvatierra O; Sarwal MM
    Pediatr Transplant; 2008 Sep; 12(6):701-7. PubMed ID: 18179640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reviewing the evidence for de novo immunosuppression with sirolimus.
    Flechner SM
    Transplant Proc; 2008 Dec; 40(10 Suppl):S25-8. PubMed ID: 19100902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale and criteria of eligibility for calcineurin inhibitor interruption following kidney transplantation.
    Danger R; Giral M; Soulillou JP; Brouard S
    Curr Opin Organ Transplant; 2008 Dec; 13(6):609-13. PubMed ID: 19060551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing early withdrawal or avoidance of steroids with standard steroid therapy in kidney transplant recipients.
    Hricik DE
    Nat Clin Pract Nephrol; 2008 Jul; 4(7):360-1. PubMed ID: 18477989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991-2005.
    Chang SH; Russ GR; Chadban SJ; Campbell S; McDonald SP
    Nephrology (Carlton); 2008 Apr; 13(2):171-6. PubMed ID: 18275507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
    Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current issues in pediatric transplantation.
    Kelly DA
    Pediatr Transplant; 2006 Sep; 10(6):712-20. PubMed ID: 16911496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunosuppression in renal transplantation: some aspects for the modern era.
    Chadban S; Morris R; Hirsch HH; Bunnapradist S; Arns W; Budde K
    Transplant Rev (Orlando); 2008 Oct; 22(4):241-51. PubMed ID: 18657962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Success of a steroid-minimization immunosuppression protocol for renal transplantation in the presence of donor-specific antibodies.
    Butani L; Perez RV; Gallay BJ
    Pediatr Transplant; 2009 Aug; 13(5):624-7. PubMed ID: 18992067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ageing and immunosuppression in kidney transplantation.
    Land WG
    Exp Clin Transplant; 2004 Dec; 2(2):229-37. PubMed ID: 15859933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modern approaches to combining sirolimus with calcineurin inhibitors.
    Stevens RB
    Transplant Proc; 2008 Dec; 40(10 Suppl):S21-4. PubMed ID: 19100901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical factors associated with graft fibrosis in kidney-transplant recipients on steroid-avoidance immunosuppression.
    Heilman RL; Chakkera HA; Reddy KS; Colby TV; Moss AA; Williams JW; Mazur MJ; Petrides S; Mulligan DC
    Clin Transplant; 2008; 22(3):309-15. PubMed ID: 18482051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunosuppression in the elderly renal allograft recipient: a systematic review.
    Montero N; Pérez-Sáez MJ; Pascual J; ; ; Abramowicz D; Budde K; Dudley C; Hazzan M; Klinger M; Maggiore U; Oberbauer R; Pascual J; Sorensen SS; Viklicky O
    Transplant Rev (Orlando); 2016 Jul; 30(3):144-53. PubMed ID: 27279024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The potential for tolerance in pediatric renal transplantation.
    Traum AZ; Ko DS; Kawai T
    Curr Opin Organ Transplant; 2008 Oct; 13(5):489-94. PubMed ID: 19060531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
    Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients.
    Demirjian S; Stephany B; Abu Romeh IS; Boumitri M; Yamani MH; Poggio ED
    Clin Transplant; 2009; 23(3):351-60. PubMed ID: 19208105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.